JP2009510043A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009510043A5 JP2009510043A5 JP2008532873A JP2008532873A JP2009510043A5 JP 2009510043 A5 JP2009510043 A5 JP 2009510043A5 JP 2008532873 A JP2008532873 A JP 2008532873A JP 2008532873 A JP2008532873 A JP 2008532873A JP 2009510043 A5 JP2009510043 A5 JP 2009510043A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- alkyl
- independently
- formula
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims 55
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 53
- 125000000217 alkyl group Chemical group 0.000 claims 51
- 229910052799 carbon Inorganic materials 0.000 claims 36
- 229910052757 nitrogen Inorganic materials 0.000 claims 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 29
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 25
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 125000001153 fluoro group Chemical group F* 0.000 claims 14
- -1 (cyclopropyl) methyl- Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 11
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 11
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000004076 pyridyl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 6
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 5
- 150000001721 carbon Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 229930194542 Keto Natural products 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 2
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 229910005965 SO 2 Inorganic materials 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000000468 ketone group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 125000004848 alkoxyethyl group Chemical group 0.000 claims 1
- 125000004849 alkoxymethyl group Chemical group 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000003401 eosinophilic granuloma Diseases 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000003419 tautomerization reaction Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72159705P | 2005-09-29 | 2005-09-29 | |
| US60/721,597 | 2005-09-29 | ||
| PCT/GB2006/003626 WO2007036733A1 (en) | 2005-09-29 | 2006-09-29 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009510043A JP2009510043A (ja) | 2009-03-12 |
| JP2009510043A5 true JP2009510043A5 (https=) | 2009-11-12 |
| JP5323484B2 JP5323484B2 (ja) | 2013-10-23 |
Family
ID=37685723
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532874A Pending JP2009510044A (ja) | 2005-09-29 | 2006-09-29 | ピラゾロ［３，４−ｂ］ピリジン化合物及びそのＰＤＥ４阻害薬としての使用 |
| JP2008532873A Expired - Fee Related JP5323484B2 (ja) | 2005-09-29 | 2006-09-29 | ピラゾロ［３，４−ｂ］ピリジン化合物及びそのＰＤＥ４阻害薬としての使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532874A Pending JP2009510044A (ja) | 2005-09-29 | 2006-09-29 | ピラゾロ［３，４−ｂ］ピリジン化合物及びそのＰＤＥ４阻害薬としての使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20080255186A1 (https=) |
| EP (2) | EP1940835B1 (https=) |
| JP (2) | JP2009510044A (https=) |
| AT (1) | ATE503756T1 (https=) |
| DE (1) | DE602006021044D1 (https=) |
| ES (1) | ES2363795T3 (https=) |
| WO (2) | WO2007036733A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE503756T1 (de) * | 2005-09-29 | 2011-04-15 | Glaxo Group Ltd | Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren |
| GB0614570D0 (en) * | 2006-07-21 | 2006-08-30 | Glaxo Group Ltd | Compounds |
| SI2046787T1 (sl) | 2006-08-01 | 2011-07-29 | Glaxo Group Ltd | Pirazolo(3,4-b)piridinske spojine in njihova uporaba kot PDE4 inhibitorji |
| DK2124944T3 (da) * | 2007-03-14 | 2012-04-23 | Ranbaxy Lab Ltd | Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer |
| KR20100017297A (ko) | 2007-04-26 | 2010-02-16 | 다케다 야쿠힌 고교 가부시키가이샤 | ２환식 화합물 및 이의 약학적 용도 |
| WO2009100169A1 (en) * | 2008-02-06 | 2009-08-13 | Glaxo Group Limited | Dual pharmacophores - pde4-muscarinic antagonistics |
| EP2249830A4 (en) * | 2008-02-06 | 2012-07-18 | Glaxo Group Ltd | DUAL PHARMACOPHORES, ANTAGONISTS OF MUSCARINIC RECEPTORS AND INHIBITORS OF PDE4 ACTIVITY |
| JP2012502977A (ja) * | 2008-09-19 | 2012-02-02 | ランバクシー ラボラトリーズ リミテッド | ホスホジエステラーゼ阻害薬 |
| AU2010219097A1 (en) | 2009-01-13 | 2011-08-04 | Glaxo Group Limited | Pyrimidinecarboxamide derivatives as inhibitors of SYK kinase |
| WO2011113512A1 (de) * | 2010-03-16 | 2011-09-22 | Merck Patent Gmbh | Morpholinylchinazoline |
| US8487102B2 (en) * | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
| US20140113898A1 (en) * | 2010-11-08 | 2014-04-24 | Zalicus Pharmaceuticals Ltd. | Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers |
| EP2574607A1 (en) * | 2011-09-06 | 2013-04-03 | F. Hoffmann-La Roche AG | PDE10 modulators |
| US9243001B2 (en) | 2013-03-15 | 2016-01-26 | Epizyme, Inc. | Substituted benzene compounds |
| CA2903572A1 (en) * | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
| US9011934B2 (en) | 2013-06-14 | 2015-04-21 | SatisPharma, LLC | Multi-purpose anti-itch treatment |
| EP3102576B8 (en) | 2014-02-03 | 2019-06-19 | Vitae Pharmaceuticals, LLC | Dihydropyrrolopyridine inhibitors of ror-gamma |
| DE102014009164A1 (de) * | 2014-06-03 | 2015-12-03 | Herbalist & Doc Gesundheitsgesellschaft Mbh | Silikonölhaltige nasal anzuwendende Formulierungen |
| PT3207043T (pt) | 2014-10-14 | 2019-03-25 | Vitae Pharmaceuticals Llc | Inibidores de di-hidropirrolopiridina de ror-gama |
| US9452178B1 (en) | 2014-10-22 | 2016-09-27 | SatisPharma, LLC | Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| WO2017024018A1 (en) | 2015-08-05 | 2017-02-09 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| CN110121498A (zh) | 2016-12-20 | 2019-08-13 | 先正达参股股份有限公司 | 具有杀线虫活性的n-环丁基-噻唑-5-甲酰胺 |
| AU2018238138A1 (en) | 2017-03-21 | 2019-10-17 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
| JP2020528904A (ja) | 2017-07-24 | 2020-10-01 | ヴァイティー ファーマシューティカルズ，エルエルシー | ＲＯＲγの阻害剤 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| TW201920188A (zh) * | 2017-08-10 | 2019-06-01 | 美商美國禮來大藥廠 | [1,2,4]三唑衍生物 |
| US12582809B2 (en) | 2018-01-26 | 2026-03-24 | Bt Bidco, Inc. | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CA3168494A1 (en) * | 2020-01-23 | 2021-07-29 | Roopa Rai | Pgdh inhibitors and methods of making and using |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100387598C (zh) * | 2002-09-16 | 2008-05-14 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
| GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| ATE503756T1 (de) * | 2005-09-29 | 2011-04-15 | Glaxo Group Ltd | Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren |
-
2006
- 2006-09-29 AT AT06779578T patent/ATE503756T1/de not_active IP Right Cessation
- 2006-09-29 EP EP06779578A patent/EP1940835B1/en active Active
- 2006-09-29 EP EP06779579A patent/EP1940836A1/en not_active Withdrawn
- 2006-09-29 DE DE602006021044T patent/DE602006021044D1/de active Active
- 2006-09-29 ES ES06779578T patent/ES2363795T3/es active Active
- 2006-09-29 JP JP2008532874A patent/JP2009510044A/ja active Pending
- 2006-09-29 WO PCT/GB2006/003626 patent/WO2007036733A1/en not_active Ceased
- 2006-09-29 JP JP2008532873A patent/JP5323484B2/ja not_active Expired - Fee Related
- 2006-09-29 US US12/067,994 patent/US20080255186A1/en not_active Abandoned
- 2006-09-29 US US12/067,990 patent/US20090131431A1/en not_active Abandoned
- 2006-09-29 WO PCT/GB2006/003627 patent/WO2007036734A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009510043A5 (https=) | ||
| RU2019118623A (ru) | Пирролопиримидины в качестве потенциаторов мвтр | |
| JP7611278B2 (ja) | 金属酵素阻害剤化合物 | |
| CN105764514B (zh) | 作为tam族激酶抑制剂的氨基吡啶衍生物 | |
| CN104334529B (zh) | 用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物 | |
| US10023576B2 (en) | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | |
| TWI672292B (zh) | 作為ｐｄｅ４抑制劑之經取代之吡啶及吡化合物 | |
| JP2007529484A5 (https=) | ||
| CN102089297A (zh) | 新的1,2,4-噁二唑化合物和其使用方法 | |
| KR101363090B1 (ko) | 아자비시클로 헥산 유도체의 용도 | |
| CN101437519A (zh) | 吲唑化合物 | |
| CA2642922A1 (en) | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | |
| RU2019120990A (ru) | Бициклические гетероарильные производные в качестве стимуляторов cftr | |
| JP2010515715A5 (https=) | ||
| JP2010512419A (ja) | 医薬組成物およびそれの使用方法 | |
| JP2018524331A5 (https=) | ||
| JP2012532112A5 (https=) | ||
| JP2011513374A5 (https=) | ||
| JP2011502982A5 (https=) | ||
| JP2014001228A (ja) | Ｈ−ｐｇｄｓの阻害剤としてのマルチヘテロアリール化合物及びプロスタグランジンｄ２を介した疾患を治療するための該化合物の使用 | |
| WO2012133607A1 (ja) | ピラゾール化合物 | |
| JP2022105013A (ja) | ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用 | |
| JP2011529959A5 (https=) | ||
| CN101072757A (zh) | 苯甲酰胺衍生物对葡萄糖激酶酶的作用 | |
| JP2016520635A5 (https=) |